Stock Information
symbol line chart

MRMDMariMed Inc

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

N/A

Location

Massachusetts, USA

Exchange

OTC

Website

https://marimedinc.com

Summary

MariMed Inc.

Company Info

CEO

N/A

Location

Massachusetts, USA

Exchange

OTC

Website

https://marimedinc.com

Summary

MariMed Inc.

AI Insights for MRMD
5 min read

Quick Summary

MariMed Inc. is a U.S.-based cannabis company focused on cultivating, producing, dispensing, and licensing medical and adult-use cannabis products. The company sells branded cannabis flower, concentrates, formulations, and dispensary products, with Nature’s Heritage identified as one of its key genetics and flower brands. MariMed also licenses brands and product formulations and leases cannabis-related facilities, which gives it exposure beyond direct retail sales. Its main customers include medical cannabis patients, adult-use recreational consumers in regulated markets, dispensary shoppers, and potentially other licensed cannabis operators that use its brands or facilities. The company operates in a highly regulated and competitive cannabis market, and its OTC listing, small market capitalization, and negative earnings make it a higher-risk equity than larger publicly traded cannabis operators.

Strengths

•

MariMed’s primary strength is its participation in the regulated U.S. cannabis market, which still has long-term growth potential as medical and adult-use legalization expands.

•

The company has recognizable cannabis brand exposure through Nature’s Heritage and related product formulations.

•

Its business model includes cultivation, production, dispensing, licensing, and facility leasing, giving it multiple potential revenue streams.

•

The company’s valuation metrics, such as price-to-book value below 1 and EV-to-revenue below 1, may attract investors looking for discounted cannabis exposure.

•

MariMed also has a relatively focused operating structure compared with much larger multistate operators, which could help it adapt quickly in selected markets.

Key Risks

•

MariMed faces major regulatory risk because cannabis remains federally restricted in the United States, despite state-level legalization.

•

Changes in state regulations, licensing rules, taxation, or enforcement priorities could materially affect operations and profitability.

•

Competitive pressure from larger cannabis companies may reduce pricing power and make customer acquisition more expensive.

•

The company’s negative net income, small scale, and OTC listing increase financial and liquidity risk for shareholders.

What to Watch

The provided most recent fundamental period is Q3 2026, and the data indicates MariMed remained revenue-generating but only modestly profitable at the operating level.
Total revenue was about $41.9 million, while gross profit was about $16.2 million, showing that the company still has a meaningful gross margin base.
Operating income was positive at about $418,000, but net income was negative at about $3.6 million, which suggests that below-the-line expenses, interest, taxes, or other costs continued to weigh on results.
No specific new product launch, acquisition, partnership, or dispensary opening for MariMed is identified in the supplied quarter data.
The most notable quarterly event from the available information is therefore the mixed financial profile of revenue generation, positive operating income, and continued net losses.

Price Drivers

•

MariMed’s stock price is likely driven primarily by revenue growth, profitability trends, cash flow generation, and investor sentiment toward U.S. cannabis equities.

•

The company reported total revenue of about $41.9 million, gross profit of about $16.2 million, and operating income of about $0.4 million, but net income was negative at roughly $3.6 million.

•

Negative EPS of approximately -$0.01 means investors may focus on whether the company can convert revenue into sustainable net profitability.

•

Broader cannabis-sector catalysts, such as potential U.S. federal rescheduling, legalization momentum, tax reform, and improved access to banking, could significantly affect valuation.

•

Because MRMD trades on the OTC market with a small market capitalization and volume that can vary sharply, liquidity, retail speculation, and sector news can also move the stock materially.

Recent News

•

The most recent company-specific information in the supplied dataset is MariMed’s Q3 2026 financial update.

•

For Q3 2026, MariMed reported total revenue of approximately $41.9 million, gross profit of approximately $16.2 million, and positive operating income of approximately $418,000.

•

However, the company still posted a net loss of approximately $3.6 million, or about -$0.01 per share, after interest expense of about $2.0 million and income tax expense of about $2.0 million.

•

Q3 2026 operating expenses included about $14.3 million of selling, general, and administrative expense, $847,000 of marketing expense, $505,000 of other operating expenses, and $116,000 of restructuring charges.

•

The data does not list a specific recent MariMed acquisition, partnership, financing transaction, legal development, dispensary opening, or product launch, and no next earnings date is provided.

•

As a result, the latest identifiable news is the company’s Q3 2026 operating performance: continued revenue generation and positive operating income, offset by interest, taxes, and a continued net loss.

Market Trends

•

The cannabis market continues to be shaped by state-level legalization, medical cannabis adoption, and the gradual normalization of adult-use products.

•

Consumers are increasingly buying a wider range of cannabis products, including flower, vapes, edibles, concentrates, topicals, and wellness-oriented formulations.

•

At the same time, many cannabis stocks have struggled because of weak profitability, limited access to capital, regulatory complexity, high tax burdens, and investor skepticism.

•

Smaller OTC-listed cannabis companies can be especially volatile because liquidity is limited and sentiment toward federal reform can shift quickly.

•

For MariMed, the most important market trends are federal reform potential, pricing pressure in mature markets, demand for branded cannabis products, and consolidation among U.S. operators.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on MRMD

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

No more topics to show